Get ready to mark your calendars because the much anticipated third quarter financial results of Rhythm Pharmaceuticals (NASDAQ: RYTM) are set to be unveiled on Tuesday 5th November 2024. Investors and market watchers will have the chance to dive into the company's financial performance as the announcement is scheduled after market close.
In accordance with the forecasts of financial specialists on Wall Street, the enterprise is primed to announce an anticipated $0.80 loss per share for the quarter. Additionally, the company is projected to reveal a total revenue of $32.52 million for this particular period.
When examining the corresponding quarter from the previous year, the company's earnings report highlighted a per-share loss of $0.76. This results was derived from the company's total revenue, which reached an impressive $22.5 million during same quarter.
Analysts on Wall Street have shared their predictions regarding the annual performance of the company, estimating a total revenue of $122.96 million. Additionally, they are expecting the company to achieve per share loss of $4.47 for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.55 | +32.9% | 29.08 M | +51.3% |
| Q1 2024 | $-2.35 | -155.4% | 25.97 M | +126.4% |
| Q4 2023 | $-0.70 | +6.7% | 24.23 M | +175.7% |
| Q3 2023 | $-0.76 | +3.8% | 22.50 M | +425.3% |
| Q2 2023 | $-0.82 | +7.9% | 19.22 M | +112.0% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 5th November 2024 at 05:00 PM eastern time, in a conference call with public.
Rhythm Pharmaceuticals (RYTM) closed Friday's regular trading session at $49.01, reflecting a 2.68 percent rise. The stock fluctuated between $47.88 and $50.07 during the day, with a volume of 293.90 thousand shares.
